Market Update (NYSE:MDT): Medtronic’s Valiant® Thoracic Stent Graft System Demonstrates Durability After Five Years

[GlobeNewswire] – Valor II U.S. Study Shows Strong Safety and Efficacy in Treatment of Thoracic Aortic Aneurysms DUBLIN and Newport, R.I. – October 5, 2015 – Medtronic plc ( NYSE:MDT ) today announced . . . → Read More: Market Update (NYSE:MDT): Medtronic’s Valiant® Thoracic Stent Graft System Demonstrates Durability After Five Years Similar Articles: Market Update: Medtronic Inc (NYSE:MDT) – Medtronic says trials find gene linked to sudden cardiac death Stock Update: Medtronic Inc (NYSE:MDT) – Medtronic Starts Clinical Study of Endurant Evo AAA Stent Graft System for Endovascular Treatment of Abdominal Aortic Aneurysms Market Update: Medtronic Inc (NYSE:MDT) – Medtronic Begins Enrollment in Feasibility Study of Valiant ‘Mona LSA’ Branch Thoracic Stent Graft System